LBT

0.00%

1.9¢ lbt innovations limited

Crunch Time, page-2

First 2 Last

Share
Profile

Follow
Smoking

936 Posts.

90

17/09/18

17:51

Post #: 35653172
Share

Originally posted by Callahan70 ↑

I am extremely confident that the next 2 months will see a substantial rise in price for the very simple reason that its crunch time, IMHO only.

You can’t go to another AGM and present the next 12 months objectives when you haven’t achieved any from the year before…..Maybe they can try excuses but I guess but that’s wearing a bit thin, more elephants in the room maybe.

CY18 Key Objectives as per 2017 AGM Presentation were
Extend APAS analysis modules Not done yet, That we know
Sales of APAS in Australia and NZ Only one sale
Sales of APAS in targeted European countries No sales achieved
Sales of APAS in USA No Sales achieved
Signing of distribution agreement Not done yet
FDA 510K supplement cleared for APAS Independence Not done yet
CE Marking for APAS No word
Market research for Woundvue Shelved
RAH 6 month review of Woundvue No word

These were all in the AGM presentation last year
12 months and none of the objectives have been met.

In the last AGM presentation, they Bragged that FDA Clearance introduced volatility in the stock but gave the Sustainable doubling of market price post FDA Clearance. Never mind that the share price at the AGM was 0.26.

They got FDA clearance on the 10th October 2016 the day before the price was 0.19 that would mean a price today of 0.38 cents. Now its 10 cents

Capital raise in Dec 16 at 0.31 Now 0.10c down 66%
Failed SPP May 17 at 0.26 Now 0.10c down 58%
Oct 17 Microstreak to Chinese for issue of $ 2 m in shares at 0.31 now 0.10c down 66%
March 2018 another Capital raise and SPP this time at 0.15c Now 0.10c down 33%
And what about all those that brought after FDA, Glad I didn’t know about it.

Its crunch time, time for results and it has to be before the AGM.
Current market cap lower than just the development cost of APAS.
Hence, I expect the price to rise as some of these objectives have to be met and met now, time is running out.
It’s now or never. RESULTS must be forth coming

They have a wonderful machine, great AI, patented and proven and potential royalties of $60,000,000 on just 1500 machines.
Never mind the profit share on the sales of the machine.
In my humble opinion.
60 million puts this young pup in the realms of a young Cochlear.
60,000,000 earnings divided by 200,000,000 shares is $3.00 at a PE Ratio of 1 LOL
LOL, but its no longer funny.

Expand

People need to know their limitations - if you can't deliver then step aside and get someone better to deliver on what you have failed to achieve.

The best thing BB can do for all stakeholders is acknowledge his shortcomings and move on.

2 years and no objectives achieved is a fail in any language.

If the board doesnt make the changes then they need to be rolled too.

LBT Price at posting: 10.0¢ Sentiment: Hold Disclosure: Held
6 Upvote

2 Great analysis

Reply

Top Stories

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

VGL

TruScreen Group launches five-year cervical screening program in Ho Chi Minh City

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

There are more pages in this discussion • 82 more messages in this thread...

First 2 Last

Add LBT (ASX) to my watchlist

(20min delay)
Last 1.9¢		Change 0.000(0.00%)		Mkt cap ! $23.13M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
1	1819	1.9¢

Sellers (Offers)

Price($)	Vol.	No.
1.9¢	278267	1

View Market Depth

No.	Vol.	Price($)
1	2173	0.082
1	888	0.076
1	28682	0.070
1	5000	0.065
1	100000	0.062

Price($)	Vol.	No.
0.083	32748	1
0.084	58888	1
0.087	28000	1
0.089	50000	1
0.090	89000	2

Last trade - 07.02am 25/11/2024 (20 minute delay)

LBT (ASX) Chart

Day chart unavailable

Crunch Time, page-2

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

TruScreen Group launches five-year cervical screening program in Ho Chi Minh City

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Crunch Time, page-2

Top Stories

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

TruScreen Group launches five-year cervical screening program in Ho Chi Minh City

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News